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http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanBackground: Escherichia coli is a frequent causative agent of urinary tract infections, and
increasing resistance of E. coli to antimicrobials presents a growing challenge.
Methods: Here we compare phenotypes of extended-spectrum b-lactamase (ESBL) producers
(n Z 220) with a control group of sensitive strains (non-ESBL producers; n Z 150). For each
strain, we assessed the presence of O25 antigen, hemolysis, biofilm production, sensitivity
to antibiotics, and biochemical profile.
Results: Compared to the control group, ESBL producers were more frequently O25 positive
(6.0% vs. 42.3%) and less frequently hemolytic (34.7% vs. 6.4%). Comparison of biofilm produc-
tion in braineheart infusion (BHI) and in BHI with 4% glucose supplementation showed that
ESBL-positive strains produced biofilm in BHI with glucose less intensely than the control group
(p < 0.05). Most ESBL producers were ciprofloxacin-resistant (91.8%). Biochemical analyses re-
vealed that ESBL producers more frequently utilized inositol, ornithine, sorbitol, melibiose,
and saccharose, whereas the control group more frequently used esculin, lysine, arginine,
and dulcitol. The control group strains with O25 antigen were more commonly resistant to cip-
rofloxacin (p < 0.05). Pulsed-field gel electrophoresis results showed higher variability among
the control group of sensitive strains.
Conclusion: These findings suggest a potential to detect ESBL strains based on virulence factorsof Microbiology, Faculty of Medicine, Masaryk University and St. Anne’s University Hospital, Pekarska´
i.cz (V. Woznicova´).
.04.010
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330 P. Siskova´ et al.and biochemical properties, which could be useful in shaping proper empiric antimicrobial
therapy, and for initiating such therapy as soon as possible.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Escherichia coli is one of the most frequently isolated
causative agents of urinary tract infections (UTIs), and is
responsible for about 50% of nosocomial UTIs,1,2 as well as
70e95% of community-acquired infections.1,2 UTIs are
usually mild infections; however, they have the potential to
lead to sepsis and death.3 Severe UTIs are especially
dangerous to immunodeficient individuals, patients with
congenital abnormalities,4 obstruction of the urinary
tract,1 and diabetics.5,6 Characteristic virulence factors in
uropathogenic E. coli strains include cytotoxic necrotizing
factors, a-hemolysin, adhesins, siderophores, and resis-
tance to complement,7 the presence of which influences E.
coli survival in the urinary tract.
Molecular biology analyses indicate that the vast ma-
jority of extraintestinal E. coli belong to the phylogenetic
group B2.8,9 Although the strains of this group possess the
highest number of specific genes, studies have found no
specific virulence gene differentiating extraintestinal
strains from gut commensal E. coli.8,10 This suggests that
the extraintestinal strains have developed from the gut
ones.10 Intestinal strains remain a frequent cause of UTIs in
otherwise healthy individuals.1 Transfer of E. coli from the
gut to the urinary tract causes rapid changes in bacterial
metabolism.8 The gut environment is nutrient rich, with
plenty of carbohydrates to support E. coli metabolism. By
contrast, the urinary tract environment typically has a high
osmolarity and abundance of nitrogenic compounds, but
lacks oxygen and iron.8 In response to the low concentra-
tion of iron in urine, bacteria express an array of side-
rophores.11 E. coli uses short peptides and amino acids as a
source of energy,8 and the presence of accessible nutrients
affects individual metabolic processes.8,12
For many years, the treatment of UTIs caused by E. coli
was straightforward. However, this situation changed in the
1980s when resistance to high-generation cephalosporins
emerged,13 and was quickly transferred to E. coli. Treat-
ment has been substantially complicated by the spreading
of extended-spectrum b-lactamase (ESBL) producers along
with other types of resistance (e.g., resistance to amino-
glycosides and carbapenems).3 Recent reports have
described the growing importance of the O25b:H4-ST131
strain, which is linked to multiresistance,14 especially to
fluoroquinolones.15,16 Strains bearing the O25 antigen
frequently cause life-threatening complications in renal
transplant patients.17
Additionally, catheterized patients are at high risk of
biofilm development in the catheter. Biofilm production is
affected by a range of external factors and is highly
dependent on bacterial metabolism, especially acetate
metabolism.18 Acetate formation can be influenced byglucose concentration.12 Growth in a biofilm, when
compared with planktonic, substantially reduces bacterial
antibiotic sensitivity and influences the growth rate.
Growth of bacteria in a biofilm may also indicate higher
clinical significance of an isolate.19
Early diagnosis of UTI causative agents, especially those
that are antibiotic resistant, is crucial to adequate antibi-
otic therapy. The development of molecular biological
methods has improved diagnostic accuracy; however, such
methods are also more expensive and potentially more time
consuming. Classical (nonmolecular) methods have the
advantages of lower cost and the fact they can be pro-
cessed at almost any laboratory without a need for the
expensive facilities that are required for molecular bio-
logical methods. Studies have reported that antimicrobial
resistance among uropathogenic E. coli is influenced by
phenotypic features,20,21 the loss of virulence factors,21 or
even bacterial metabolism.8 Thus, the present study aimed
to compare phenotypic features of ESBL-positive urinary
isolates of E. coli with strains that are sensitive to basic b-
lactam antibiotics (e.g., ampicillin and cephalothin), and to
assess whether they could be distinguished based on the
presence of certain virulence factors and their biochemical
properties.
Materials and methods
Between 2008 and 2011, we collected 220 strains of
ESBL-producing E. coli from urine as a part of the routine
UTI diagnostics at the Department of Microbiology, St
Anne’s Teaching Hospital and the Faculty of Medicine,
Masaryk University, Brno, Czech Republic. All strains were
isolated in a quantity of at least 105 colony-forming units/
mL. As controls, we used 150 strains of ESBL-negative E.
coli sensitive to the following b-lactam antibiotics:
ampicillin, amoxicillin-clavulanate, cephalothin, ceftazi-
dime, and cefotaxime. The strains were divided according
to their origin: hospital strains and strains from outpatient
clinics.
Antibiotic sensitivity, hemolysis, and serotyping
In all strains, we evaluated sensitivity to ciprofloxacin,
ertapenem, and gentamicin using the disc sensitivity test
according to the Clinical and Laboratory Standards Institute
criteria. For ESBL assessment, we used both the double-disc
synergy test, and the Clinical and Laboratory Standards
Institute test.22 Only ESBL-positive/ampC-negative strains
were included in the study.
Hemolysis was tested on blood agar with sheep eryth-
rocytes. After overnight cultivation at 37C, we assessed
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To assess the number of strains with O25 antigen in each
group, we used antiserum O25 (Denka Seiken, Tokyo,
Japan) to perform the agglutination test. In positive strains,
agglutination was visible within 1 minute.Biofilms
Biofilm production was tested in microtitration plates for
tissue cultures. Biofilm production was tested in
braineheart infusion (BHI), using the method of Stepanovic
et al.23 The results were interpreted as described by
Stepanovic et al.23 Similarly, we also tested biofilm pro-
duction in BHI (HiMedia Laboratories, Mumbai, India) with
4% glucose supplementation.Biochemical profiling
Biochemical profiles were assessed using ENTEROtest 24
(Erba Lachema, Brno, Czech Republic), which assesses
utilization of indole, hydrogen sulfide, lysine, ornithine,
urease, arginine, Simmons-citrate, malonate, phenylala-
nine, b-galactosidase, inositol, adonitol, cellobiose, sac-
charose, trehalose, mannitol, acetoin, esculin, sorbitol,
rhamnose, melibiose, raffinose, dulcitol, and glucose. To
each substrate, we added 100 mL of the strain suspended in
saline (McFarland 1.0). We used paraffin oil to test indole,
hydrogen sulfide, lysine, ornithine, urease, and arginine
utilization under anaerobic conditions. The plate was
cultured overnight at 37C, and the results read and
recorded the next day according to the manufacturer’s
instructions.Table 1 Comparison of biochemical profiles among
extended-spectrum b-lactamase (ESBL)-producing strains
and the control groupa
Substrate Positive reactions (%) Fisher’s exact
test (p)ESBL producers
(n Z 220)
Control group
(n Z 150)
Lysine 63.2 93.3 <0.001
Ornithine 88.2 78.7 0.028
Arginine 8.6 47.3 <0.001
Inositol 20.9 0.0 <0.001
Saccharose 89.6 40.0 <0.001Pulsed-field gel electrophoresis
Genetic diversity of the strains was assessed using pulsed-
field gel electrophoresis (PFGE) analysis of 10% of the E. coli
strains, which were randomly selected using SPSS version 18
(IBM Corp., Armonk, NY, USA). These strains were cultured
and processed according to the instructions for Gram-
negative bacteria.24 Restriction analysis was performed
using XbaI (New England BioLabs, Ipswich, MA, USA). The
results were evaluated using BioNumerics 6.5 (Applied
Maths, Kortrijk, Belgium) with unweighted pair group
method with arithmetic mean analysis and Pearson corre-
lation coefficient (0.5%). A phylogenetic dendrogram was
constructed based on PFGE fingerprint profiles, and the
fingerprint profiles of the ESBL and non-ESBL strains
compared.Esculin 1.4 7.3 0.004
Sorbitol 99.1 95.3 0.018
Dulcitol 4.6 12.7 0.006
Melibiose 95.9 91.3 0.049
a No statistically significant difference was demonstrated for
adonitol, cellobiose, trehalose, mannitol, rhamnose, or raffi-
nose (p > 0.05). All reactions were positive for indole, b-
galactosidase, and glucose. No reactions were positive for
hydrogen sulfide, urease, Simmons citrate, malonate, phenyl-
alanine, or acetoin.Statistical analysis
Statistical analysis was performed using the SPSS program.
Categorical data were evaluated using Fisher’s exact test.
For comparison of biofilm development (i.e., for numerical
data), the Wilcoxon test or ManneWhitney test was used. In
all cases, p < 0.05 were considered to be statistically
significant.Results
ESBL producers
A majority of the ESBL-producing strains were isolated from
women (62.7%) and from elderly patients (median age,
72 years; range, 16e96 years). Most samples originated
from bed units of Brno hospitals (79.1%). Among ESBL pro-
ducers, the vast majority of strains were sensitive to
gentamicin (97.7%) and ertapenem (100.0%), whereas only
8.2% of the strains were sensitive to ciprofloxacin. The
ciprofloxacin-sensitive strains significantly differed from
the rest of the group in an array of features. Compared with
the rest of the group, the ciprofloxacin-sensitive strains
more frequently produced biofilm in BHI (p Z 0.015),
showed greater use of lysine (p Z 0.021) and raffinose
(pZ 0.009), and showed less use of saccharose (pZ 0.001)
and ornithine (p Z 0.011). Biochemical analyses also
showed that the strains isolated from hospitalized patients
utilized lysine much less than strains isolated from out-
patients (p Z 0.025).
The ESBL-producing strains were rarely hemolytic
(6.4%). O25 antigen was detected in 42.5% of ESBL pro-
ducers; these strains were typically nonhemolytic
(p Z 0.047) and showed greater usage of inositol
(p Z 0.013), ornithine (p Z 0.037), and saccharose
(pZ 0.044). Among the ESBL producers, only nonhemolytic
strains utilized inositol (pZ 0.045). Table 1 summarizes the
abilities of ESBL producers to utilize individual substrates.
The most variable results were obtained for lysine and
saccharose. Lysine positive strains tended to be inositol
positive (p Z 0.003), raffinose positive (p Z 0.012), and
saccharose negative (p Z 0.001). Strains utilizing saccha-
rose tended to be ornithine negative (p Z 0.037) and
raffinose negative (p < 0.001), and more frequently pro-
duced biofilm in BHI with glucose (p Z 0.007).
Table 2 Typical diagnostic features of extended-
spectrum b-lactamase (ESBL) producers and control (non-
ESBL) strains
Diagnostic features Likely
classification
1. Nonhemolytic strain ESBL producer
2. O25 positive (often resistant
to fluoroquinolones)
3. Inositol/saccharose/ornithine
positive
4. Biofilm production not influenced
by 4% glucose
1. Hemolytic strain Non-ESBL
2. Non-O25 antigen (often sensitive
to fluoroquinolones)
3. Lysine/arginine/esculin/dulcitol
positive
4. Biofilm production more intense
with 4% glucose
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(72.7%), and in BHI with 4% glucose supplement (53.7%).
The optical densities of biofilm produced in the two broths
did not differ significantly (p Z 0.148). The ESBL-positive
biofilm-producing strains were, according to Stepanovic
et al,23 typically weak producers in both media.
Control group
Like the ESBL-producing strains, control strains were also
isolated from predominantly female patients (77.3%), but
the control strains were isolated from younger patients
than those of the ESBL group. Within the control group, the
E. coli strains isolated from males were more often hemo-
lytic (pZ 0.041), arginine positive (pZ 0.031), and esculin
positive (p Z 0.017) than strains from females. The ma-
jority of strains (71.3%) were cultured from the urine of
outpatients, or from samples sent from general practi-
tioners. Compared with the strains from hospitalized pa-
tients, the control strains from outpatients and general
practitioners less frequently produced biofilm in BHI
(p Z 0.037).
The control strains were highly sensitive to basic antibi-
otics, as well as to the other tested antimicrobials. All strains
were sensitive to ertapenem and gentamicin, and 96.7% of
strains were sensitive to ciprofloxacin. The ciprofloxacin-
resistant strains were often also O25 positive (p Z 0.029).
About one-third of the strains were hemolytic (34.7%), and
these strains less frequently produced biofilm in BHI with
glucose (p Z 0.0399) and showed greater use of ornithine
(pZ 0.005) and arginine (pZ 0.002). Agglutination with O25
antigen was positive in only 6.0% of strains, and these strains
more frequently utilized saccharose (pZ 0.032).
Over half of the control strains produced biofilm in BHI
(66.0%) and in BHI with glucose (68.7%). Optical density
analysis confirmed differing biofilm production between the
two broths (pZ 0.037). The control strains were, according
to Stepanovic et al,23 typically weak biofilm producers in
BHI, and moderate biofilm producers in BHI with glucose.
Moreover, biofilm in BHI was less frequently produced by
the saccharose positive (p Z 0.014) and esculin positive
control strains (p Z 0.008).
Table 1 summarizes the overall biochemical profile of
the control group. Individual biochemical features varied in
regards to esculin, ornithine, lysine, arginine, adonitol,
raffinose, and saccharose. Esculin utilizing control strains
tended to be rhamnose negative (p Z 0.020) and raffinose
positive (p Z 0.007). Almost four-fifths of control strains
were ornithine positive, and these strains were significantly
more frequently lysine positive (p Z 0.001), saccharose
positive (p < 0.001), dulcitol negative (p Z 0.029), and
adonitol negative (p Z 0.007). We also observed that the
saccharose positive strains tended to also be raffinose
positive (p Z 0.036).
Comparison of phenotypic features between the
ESBL group and the control group
A slight predominance of ESBL producers (59.5%) was in
tested E. coli strains. ESBL producers were mostly isolated
from hospitalized patients (79.1%), whereas control strainswere more frequent in outpatients (71.3%). O25-positive
strains were more frequently found in the ESBL group
(p < 0.001), whereas hemolysis was more common among
control strains (p < 0.001; Table 2). Biofilm production in
BHI without supplementation did not differ significantly
between the two groups (p Z 0.507). However, in BHI
supplemented with 4% glucose, the control group showed
significantly more intense biofilm production than the ESBL
group (p Z 0.029). The Enterotest 24 results confirmed
significant between-group differences in substrate utiliza-
tion (Table 1). ESBL producers utilized significantly more
inositol, ornithine, melibiose, sorbitol, and saccharose,
whereas the control group utilized significantly more
esculin, lysine, arginine, and dulcitol.
Genetic diversity analysis revealed much greater di-
versity among the control strains than among ESBL pro-
ducers (Fig. 1). The majority of ESBL strains (72.7%)
belonged to one group with a 70% similarity level. This
group was divided into two subgroups: one with a 75%, and
the other with a 90% similarity level. However, the majority
(66.7%) of the control strains did not form a group with
other control strains at a 70% similarity level (Fig. 1).
Discussion
Here we found that the ESBL-producing E. coli in our study
differed from the sensitive strains in an array of properties
and clinical characteristics. The ESBL-positive strains were
isolated mostly from hospitalized patients, whereas the
sensitive strains were more frequently community ac-
quired. Both types of strains were predominantly isolated
from females, as they generally suffer from UTIs more
often.25 We also found that E. coli virulence factors (e.g.,
hemolysis) and biochemical properties differed between
sexes, indicating higher virulence of strains isolated from
UTIs in males.
Although a-hemolysin is an important virulence factor in
E. coli,11 we found hemolysis in only 6.4% of our ESBL strains.
Figure 1. The phylogenetic dendrogram of the fingerprint
profiles in the randomly selected group of extended-spectrum
b-lactamase (ESBL) and non-ESBL producers.
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more frequently (65.6%).26 Among our control strains, we
found a higher percentage of hemolytic strains (34.7%),
which reflects a previously reported 30e56% prevalence of
the hly locus in uropathogenic E. coli strains.11
The E. coli strain O25b:H4-ST131 lacks some features
that are typical for other E. coli strains, e.g., adhesins and
a-hemolysin.16 Thus, we assume that the low prevalence of
hemolysis in our ESBL group might be caused by the rela-
tively high number of O25-positive strains within this group
(42.5% of ESBL producers). O25 strains also differed in some
biochemical properties, for example, the O25 strains of
both groups utilized saccharose more frequently than
strains with other O antigens. Furthermore, we found that
even O25-positive ESBL-negative strains were often resis-
tant to ciprofloxacin (22.2%). This result is in agreement
with studies demonstrating a correlation between CTX-M-
15-O25b positivity and resistance to fluoroquinolones,14 and
highlights the importance of serotyping in the diagnosis of
extraintestinal E. coli infections.
The b-lactamases of classes A and D are likely to be able to
inhibit biofilm production.20 We also noticed a positive link
betweenbiofilmproduction and saccharose utilization in ESBL
producers. Compared with the sensitive strains, the ESBL
strains less frequently produced biofilm in BHI with glucose,with the exception of saccharose-positive ESBL producers.
Similarly, ciprofloxacin-sensitive ESBL strainsmore frequently
produced biofilm in BHI without glucose, resembling non-ESBL
strains in this regard. These findings indicate a possible rela-
tionship between biochemical properties of E. coli and path-
ogenicity expressed as biofilm production.
Compared with ESBL producers, the control strains
exhibited higher variability of biochemical properties/uti-
lized substrates, and this was supported by the PFGE results.
However, there were also some important similarities be-
tween both E. coli groups, especially regarding saccharose
utilization. Saccharose metabolism is considerably variable
among pathogenic E. coli strains.27 In addition to the link
between the presence of the O25 antigen and saccharose-
positivity, we found a link between ornithine-positivity and
saccharose-positivity. By contrast, we noticed discordant
results between saccharose and raffinose utilization. Within
the ESBL group, these two substrates were utilized in indi-
rect proportion to each other, whereas in the control group
we noticed a direct proportion between the two. Differing
saccharose and raffinose utilization by different clusters of
E. coli has also been described.28
Interestingly, we also found a significant between-group
difference in inositol utilization. No control strain was able
to process inositol, whereas 20.9% of ESBL producers could.
Moreover, inositol utilization was more common among O25-
positive strains. It should be noted that inositol positivity is
not a typical feature of E. coli, and a potential link to inositol
phosphates has been previously discussed.29 Inositol-
positivity could be related to bacterial adhesion to the
epithelial cells of the gut, in which a previous study
demonstrated a short-term increase in inositol phosphate
production, and the interference with signal mechanisms of
the cells was assumed.29 Alternatively, this feature might be
related to inositol phosphate accumulation in the infected
area, which could interfere with signal pathways and disrupt
cell surfaces, potentially leading to cell death.30
External environment has a great influence on the resi-
dent bacteria, and there are known differences between
the metabolism of gut and extraintestinal E. coli.8 When
bacteria are exposed to a new or hostile environment,10 the
bacterial cells that adapt best will survive. Bacteria living in
the urinary tract can use various nutrients that are avail-
able due to the presence and continual production of
urine.31 The use of some substrates (e.g., lysine or arginine)
could help E. coli to maintain homeostasis in the acidic
environment typical for urine.32
In summary, the present comparison of E. coli pheno-
types revealed numerous differences in biochemical prop-
erties between ESBL producers and non-ESBL strains, even
though all strains were isolated from the same environment
(urine). These findings suggest that ESBL strains can be
detected and preliminary distinguished from sensitive
strains on the ground of virulence factors and biochemical
properties. This could be useful in shaping proper empiric
antimicrobial therapy, and for initiating such therapy as
soon as possible.Conflicts of interest
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